- Home
- ACET vs KVHI Comparison
ACET vs KVHI Comparison
Compare ACET & KVHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACET
- KVHI
- Stock Information
- Founded
- ACET 1947
- KVHI 1978
- Country
- ACET United States
- KVHI United States
- Employees
- ACET N/A
- KVHI N/A
- Industry
- ACET Biotechnology: Pharmaceutical Preparations
- KVHI Radio And Television Broadcasting And Communications Equipment
- Sector
- ACET Health Care
- KVHI Technology
- Exchange
- ACET Nasdaq
- KVHI Nasdaq
- Market Cap
- ACET 93.1M
- KVHI 108.1M
- IPO Year
- ACET N/A
- KVHI 1996
- Fundamental
- Price
- ACET $0.96
- KVHI $5.78
- Analyst Decision
- ACET Strong Buy
- KVHI
- Analyst Count
- ACET 4
- KVHI 0
- Target Price
- ACET $5.67
- KVHI N/A
- AVG Volume (30 Days)
- ACET 790.0K
- KVHI 56.4K
- Earning Date
- ACET 11-06-2024
- KVHI 11-07-2024
- Dividend Yield
- ACET N/A
- KVHI N/A
- EPS Growth
- ACET N/A
- KVHI N/A
- EPS
- ACET N/A
- KVHI N/A
- Revenue
- ACET N/A
- KVHI $118,366,000.00
- Revenue This Year
- ACET N/A
- KVHI N/A
- Revenue Next Year
- ACET N/A
- KVHI N/A
- P/E Ratio
- ACET N/A
- KVHI N/A
- Revenue Growth
- ACET N/A
- KVHI N/A
- 52 Week Low
- ACET $0.89
- KVHI $4.17
- 52 Week High
- ACET $3.77
- KVHI $6.00
- Technical
- Relative Strength Index (RSI)
- ACET 37.36
- KVHI 64.99
- Support Level
- ACET $0.91
- KVHI $5.57
- Resistance Level
- ACET $1.12
- KVHI $5.94
- Average True Range (ATR)
- ACET 0.09
- KVHI 0.19
- MACD
- ACET 0.00
- KVHI -0.02
- Stochastic Oscillator
- ACET 16.21
- KVHI 74.19
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
About KVHI KVH Industries Inc.
KVH Industries Inc provide integrated, end-to-end services, software, and hardware that support its customers' need for access to the Internet, VoIP, operations content, and entertainment services. The company also provides commercially licensed entertainment, including news, sports, music, and movies, to commercial and leisure customers in the maritime, hotel, and retail markets. The Company operates in a number of geographic areas, including internationally. The Revenues are generated from international locations, mainly consisting of Singapore, Canada, European Union countries and other European countries, countries in Africa, Asia/Pacific and the Middle East, and India.